Your browser doesn't support javascript.
loading
Dynamic differences between DNA damage repair responses in primary tumors and cell lines.
Gilbreath, Collin; Ma, Shihong; Yu, Lan; Sonavane, Rajni; Roggero, Carlos M; Devineni, Anvita; Mauck, Ryan; Desai, Neil B; Bagrodia, Aditya; Kittler, Ralf; Raj, Ganesh V; Yin, Yi.
Affiliation
  • Gilbreath C; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Ma S; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Yu L; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Sonavane R; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Roggero CM; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Devineni A; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Mauck R; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Desai NB; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Bagrodia A; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Kittler R; Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Raj GV; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: Ganesh.Raj@utsouthwestern.edu.
  • Yin Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: Yi.Yin@utsouthwestern.edu.
Transl Oncol ; 14(1): 100898, 2021 Jan.
Article in En | MEDLINE | ID: mdl-33096336
ABSTRACT
The study of DNA damage repair response (DDR) in prostate cancer is restricted by the limited number of prostate cancer cell lines and lack of surrogates for heterogeneity in clinical samples. Here, we sought to leverage our experience with patient derived explants (PDEs) cultured ex vivo to study dynamics of DDR in primary tumors following application of clinically relevant doses of ionizing radiation (IR) to tumor cells in their native 3-dimensional microenvironment. We compared DDR dynamics between prostate cancer cell lines, PDEs and xenograft derived explants (XDEs) following treatment with IR (2Gy) either alone or in combination with pharmacological modulators of DDR. We have shown that following treatment with 2Gy, DDR can be consistently detected in PDEs from multiple solid tumors, including prostate, kidney, testes, lung and breast, as evidenced by γ-H2AX, 53BP1, phospho-ATM and phospho-DNA-PKcs foci. By examining kinetics of resolution of IR-induced foci, we have shown that DDR in prostate PDEs (complete resolution in 8 h) is much faster than in prostate cancer cell lines (<50% resolution in 8 h). The transcriptional profile of DDR genes following 2Gy IR appears to be distinct between PDEs and cell lines. Pre-treatment with drugs targeting DDR pathways differentially alter the kinetics of DDR in the PDEs and cell lines, as evidenced by altered kinetics of foci resolution. This study highlights the utility of PDEs as a robust model system for short-term evaluation of DDR in primary solid tumors in clinically relevant microenvironment.
Key words